Reduced Stability and Bi-Allelic, Coequal Expression of Profilaggrin mRNA in Keratinocytes Cultured From Subjects With Ichthyosis Vulgaris  by Nirunsuksiri, Wilas et al.
Reduced Stability and Bi-Allelic, Coequal Expression of
Profilaggrin mRNA in Keratinocytes Cultured From Subjects
With Ichthyosis Vulgaris
Wilas Nirunsuksiri, She-Hui Zhang, and Philip Fleckman
Division of Dermatology, Department of Medicine, University of Washington, Seattle, Washington, U.S.A.
Ichthyosis vulgaris (IV) is an inherited scaling skin dis-
order in which expression of profilaggrin is reduced.
Previous studies have indicated that the reduction is
caused by defective post-transcriptional control of gene
expression. Here we present evidence that profilaggrin
mRNA in keratinocytes cultured from subjects with IV is
intrinsically unstable and has a shorter half-life compared
with that in normal cells. When IV-affected keratinocytes
were treated with the protein synthesis inhibitor cyclohex-
imide, the steady-state level of profilaggrin mRNA was
increased due to stabilization of the transcript. In addi-
Ichthyosis vulgaris (IV) is a scaling skin disorder inherited as anautosomal dominant trait (Wells and Kerr, 1966; McKusick,1992). The incidence of IV is estimated to be approximatelyone in 250 to one in 5300 in the general population. Clinicaldiagnosis of the disease is based upon fine, white scales on the
skin of the trunk and extensor surfaces of the extremities, hyperlinear
palms and soles, keratosis pilaris, a personal history of atopy, and a
pedigree consistent with autosomal dominant inheritance. The condi-
tion is rarely present at birth and usually observed after 3 mo of age
(Wells and Kerr, 1966). Ultrastructurally, the epidermis of affected
individuals displays absent or reduced keratohyalin granules that are
morphologically abnormal (Anton-Lamprecht and Hofbauer, 1972;
Manabe et al, 1991); however, like most dominantly inherited diseases,
clinical variability has been observed and well documented (Mevorah
et al, 1991; Fleckman and Dale, 1993). A subset of clinically affected
individuals with IV has been identified in whom the absence of
granular layer (by light microscopy) and keratohyalin (by electron
microscopy) appears to be constant (Fleckman and Brumbaugh, in
preparation).
Thus far, profilaggrin is the only molecular marker known to be
affected by the disease. Profilaggrin is a high molecular weight precursor
of filaggrin that is synthesized in the granular layer of the epidermis
and that has been shown to be a major constituent of keratohyalin
granules. Through a series of post-translational modifications, profilag-
grin is processed to filaggrin, which aggregates keratin intermediate
filaments in the lower layers of the stratum corneum (Fleckman and
Dale, 1993). Filaggrin is subsequently proteolyzed and metabolized
Manuscript received March 10, 1997; revised December 23, 1997; accepted
for publication February 10, 1998.
Reprint requests to: Dr. Philip Fleckman, Division of Dermatology, Box
356524, University of Washington, Seattle, WA 98195–6524.
Abbreviations: CHX, cycloheximide; DRB, 5,6-dichloro-1-β-D-ribofurano-
sylbenzimidazole; IV, ichthyosis vulgaris.
0022-202X/98/$10.50 · Copyright © 1998 by The Society for Investigative Dermatology, Inc.
854
tion, the number of filaggrin repeats within the profilag-
grin gene was studied. The number of filaggrin repeats
(10–12) in individuals with IV did not differ from that of
unaffected subjects. Expression of the gene was bi-allelic
and coequal in both control and affected individuals. Our
results suggest a model in which a labile ribonuclease
and a stabilizing factor may modulate the profilaggrin
mRNA steady-state level in normal cells, whereas the
stabilizing factor may be absent or functionally inactive
in IV-affected keratinocytes. Key words: epidermis/skin. J
Invest Dermatol 110:854–861, 1998
into free amino acids that are thought to play a crucial role as water-
binding components in the upper stratum corneum (Scott et al, 1982;
review see Rawlings et al, 1994). The amino-terminal portion of
profilaggrin also functions as a calcium binding domain (Presland et al,
1995). Thus, this protein has the potential to engage in various roles
during terminal differentiation. The gene for human profilaggrin is
localized on chromosome 1q21 (McKinley-Grant et al, 1989) and
contains three exons separated by two introns of 9713 and 570 bp
(Presland et al, 1992; Markova et al, 1993) (see Fig 1A). The bulk of
the coding region locates in the third exon and consists of 10–12
repeating units of filaggrin domains that are highly homologous but
not identical. The number of filaggrin repeats is inherited as an
autosomal trait (Gan et al, 1990).
Normally, expression of the profilaggrin gene is first detectable in
the granular layer. In IV-affected individuals, expression of profilaggrin
is reduced or absent in the epidermis (Sybert et al, 1985). This
biochemical abnormality correlates with the reduction in the amount
of keratohyalin granules and with the clinical severity of the disease
(Sybert et al, 1985). We have previously reported that epidermal
keratinocytes cultured from IV-affected individuals who had no detect-
able keratohyalin granules contained approximately half the amount of
profilaggrin mRNA and a low level of immunoreactive profilaggrin
protein, whereas other markers of epidermal differentiation were
expressed normally (Fleckman et al, 1987; Nirunsuksiri et al, 1995);
however, nuclear run-on analysis revealed that transcription of the
gene in IV was equivalent to normal controls, indicating defective
post-transcriptional regulation.
Evidence for regulation of gene expression by post-transcriptional
mechanisms, such as through control of mRNA stability, has been
increasing over the years (for reviews see Hentze, 1991; Peltz et al,
1991; Sachs, 1993; Belasco and Brawerman, 1993; Decker and Parker,
1994). Factors attributable to mRNA stability include specific cis-
acting RNA sequences and structures, cytoplasmic or nuclear RNA
binding proteins, and certain other factors (e.g., growth factors).
Interactions between cis- acting elements present in either 59 or 39
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untranslated regions and cellular trans-acting proteins result in either
mRNA stabilization or degradation. Some of the RNA binding
proteins have been shown to shuttle between the nucleus and cytoplasm
(Flach et al, 1994; Taupin et al, 1995; Weighardt et al, 1995).
In this report, we have further delineated the molecular basis of the
decreased steady state level of profilaggrin mRNA in IV. We determined
the stability and allelic expression of the mRNA, and studied the effect
of protein synthesis inhibitors on mRNA stability. Our results indicate
that though profilaggrin mRNA expression is bi-allelic and coequal in
both control and affected individuals, the transcript is intrinsically
unstable in IV.
MATERIALS AND METHODS
Patients The ascertainment of subjects and diagnostic criteria for IV were as
described previously (Nirunsuksiri et al, 1995). Subjects with the clinical
phenotype of IV who had no granular layer or keratohyalin granules were
studied. Unaffected, related, or age- and sex-matched individuals served
as controls.
Human keratinocyte culture Human keratinocytes were obtained from
neonatal foreskin or blister biopsies (adults) and cultured as described previously
(Nirunsuksiri et al, 1995). To ensure profilaggrin expression, cells were harvested
at least 3 d after they reached confluence. They were fed three times a week
and 24 h before harvesting except in experiments with translational and
transcriptional inhibitors, where cells were fed with fresh medium 10 h prior
to addition of inhibitors.
Additions All inhibitors were prepared freshly as concentrated stock solutions
on the day of use as follows: (i) anisomycin (Sigma, St. Louis, MO) at 10 mg
per ml in 90% ethanol and used at 10 µg per ml, anisomycin is an elongation
blocker whose function is to inhibit formation of the 80S ribosomal complex
from 60S subunits, and causes polysome stabilization (Venrooij et al, 1977;
Edwards and Mahadevan, 1992); (ii) cycloheximide (CHX, Sigma) at 10 mg
per ml in 50% ethanol–50% water and used at 30 µg per ml, CHX is an
elongation blocker that locks the ribosomes onto the mRNA causing the
formation of stabilized polysomes, but does not affect translation initiation
(Va´zquez, 1979; Koeller et al, 1991); (iii) 5,6-dichloro-1-β-D-ribofuranosyl-
benzimidazole (DRB, Sigma) at 37.5 mM in 90% ethanol and used at 65 µM,
DRB is an analog of adenosine that selectively and reversibly blocks the
synthesis of heterogeneous nuclear RNA-α precursor of cytoplasmic mRNA
(Sehgal et al, 1976); (iv) emetine (Sigma) at 10 mg per ml in water and used at
10 µg per ml, this drug inhibits protein synthesis in eukaryotes (Jimenez et al,
1977); (v) pactamycin (Upjohn, Kalamazoo, MI) at 10 mg per ml in dimethyl
sulfoxide and used at 10 µg per ml, pactamycin is an initiation inhibitor that
acts by stabilizing the 40S-met-tRNA initiation complex and preventing the
60S ribosomal subunit from binding, thus destabilizing the polysome (Va´zquez,
1979; Chomczynski and Sacchi, 1987; Hua and Hod, 1992); (vi) puromycin
(Sigma) at 10 mg per ml in phosphate buffered saline and used at 10 µg per
ml, puromycin is an analog of the incoming aminoacyl-tRNA, hence it blocks
elongation and causes premature release of the peptide chain and the ribosomes,
resulting in polysome-free mRNA (Va´zquez, 1979).
RNA isolation, northern blot analysis, and nuclear run-on assays Total
RNA was isolated according to the method of Chomczynski and Sacchi (1987),
fractionated on glyoxal gels, transferred to Genescreen Plus (Du Pont NEN,
Boston, MA) by capillary blotting, and hybridized to radiolabeled DNA probes
listed below: profilaggrin-exon 3 (see Fig 1A) (Nirunsuksiri et al, 1995); keratin
1 39-end specific probe (a gift from Dr. D. Roop, Baylor College of Medicine;
Nirunsuksiri et al, 1995); loricrin 39-end specific probe (Nirunsuksiri et al,
1995); GAPDH (ATCC, Rockville, WI); and HS26 cDNA for human S26
ribosomal protein (a gift from Dr. P. Fort, Montpellier Cedex, France, see
Nirunsuksiri et al, 1995).
All northern blots were reprobed with GAPDH cDNA to ascertain equal
RNA loadings. After autoradiography, the blots were scanned using the
PhosphorImager (Molecular Dynamics, Sunnyvale, CA) and quantified using
image analysis software (ImageQuant Version 3.22, Molecular Dynamics).
Comparisons between hybridization signals were based on equal GAPDH signals.
To resolve the two allelic profilaggrin transcripts, total RNA was electro-
phoresed on 0.8% agarose gels at 50 mA (constant milliamperes) for 8–10 h.
Isolation of nuclei and run-on transcription was performed as described
elsewhere (Nirunsuksiri et al, 1995).
Estimation of mRNA half-life RNA stability was measured with the use
of RNA synthesis inhibitors. Keratinocytes were fed with fresh medium 10 h
before addition of 65 µM DRB. The drug concentrations utilized here were
based upon effective doses in several other cell systems (Harrold et al, 1991;
Edwards and Mahadevan, 1992; Scammell and Valentine, 1994). We found that
DRB was not toxic to the cells under the conditions used as no apparent changes
in the cultures were detected by inverted phase microscopy. Furthermore, the
yield of total RNA obtained from control and DRB-treated cells was similar.
In three separate experiments total RNA was isolated from duplicate dishes of
three distinct pairs of IV and control cell lines at different times (0, 2, 4, 8, 10,
and 12 h) after addition of inhibitors, and analyzed by northern blot hybridization.
Intensities of hybridization signals were quantified from blots as described
earlier. The ratio between profilaggrin and GAPDH mRNA signals was plotted
using the SigmaPlot program (Jandel Scientific, San Rafael, CA), and lines
were drawn to connect data points. Because the number of determinations
(three per group) of half-life was small and there was some variation between
the cell lines, the data were analyzed by group (i.e., normal versus IV), by
subject (individual cell lines), and by time (times after addition of RNA synthesis
inhibitor) using a fitted repeated measures model in the PROCMIX program
of SAS (1992).
Human genomic DNA isolation and analysis Genomic DNA was isolated
either from cultured fibroblasts using the method described previously (Miller
et al, 1988) or from peripheral blood leukocytes using modifications of the
standard procedure (Sambrook et al, 1989). Genomic DNA (5 µg) was digested
with EcoRV (Biolabs, Beverly, MA) according to the manufacturer’s conditions
and electrophoresed on a 0.8% agarose gel in tris-acetate-ethylenediamine
tetraacetic acid buffer (0.04 M Tris-acetate and 0.001 M ethylenediamine
tetraacetic acid) at 10 V per cm for 18 h. The gel was then blotted onto
Genescreen plus, and hybridized to the exon 3 filaggrin domain probe. The
number of filaggrin repeats was calculated based on the size of EcoRV restriction
fragments; this enzyme cuts on either side of exon 3, which contains the
multiple filaggrin domain (Gan et al, 1990).
RESULTS
Profilaggrin mRNA expression begins after confluence in cul-
tured keratinocytes To determine if IV influences the pattern of
profilaggrin mRNA accumulation in vitro over time, keratinocytes
from both normal and IV-affected individuals were allowed to grow
and differentiate for up to 2 wk after reaching confluence. Northern
blotting was used to assess the steady-state levels of profilaggrin mRNA
over the period when keratinocytes transit from subconfluence to
confluence. Expression of profilaggrin mRNA began as the cells
approached confluence; the level increased to a maximum around day
3 after confluence and then decreased thereafter (Fig 1B, C). This
result was seen with RNA extracted from both normal and IV-affected
keratinocytes, indicating that IV had no influence on the profile of
profilaggrin mRNA accumulation in vitro. Expression profiles of other
markers of differentiation such as K1 and loricrin are also shown and
resemble that of profilaggrin.
Profilaggrin mRNA half-life is reduced in IV keratinocytes Our
previous studies have demonstrated that profilaggrin mRNA levels in
IV-affected keratinocytes are decreased to 30–60% of normal controls,
and the decrease does not reflect diminished transcription (Nirunsuksiri
et al, 1995); however, the reduced mRNA level may be explained on
the basis of more rapid mRNA turnover. To test this hypothesis, the
half-life of profilaggrin mRNA was determined. The experiment was
performed on three different pairs of IV and control cell lines in three
separate experiments using the transcription inhibitor DRB for various
times to block de novo transcription (Fig 2). The data were analyzed
as described in Materials and Methods using a fitted repeated measures
model in the PROCMIX program of SAS. The analysis showed a
significant difference between the control and IV groups (p 5 0.0254),
with a strong difference between times (p , 0.001), indicating that
the rate of decrease of profilaggrin mRNA for the IV group was faster
than that of the normal control during the first 2 h. Thereafter, the
rate of decrease between the two groups was similar. Computed
estimates from the analysis (Table I) also indicated that the half-life of
profilaggrin mRNA in the IV group was within the first 2 h after the
addition of RNA synthesis inhibitor, whereas that in normal was longer
than 12 h.
The averaged half-life of the profilaggrin mRNA based on normaliza-
tion to GAPDH was µ2.2 h in IV-affected keratinocytes and greater
than 9 h in normal control (based on one control, see explanation in
Fig 2). GAPDH mRNA was used for normalization because of its
relatively long half-life (Genovese and Milcarek, 1990; Daujat et al,
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Figure 1. Profilaggrin mRNA is expressed after confluence in cultured
keratinocytes. (A) The structure of the profilaggrin gene. The region covered by the
probe (a filaggrin repeat unit in exon 3) used in hybridization is indicated as ‘‘3’’. (B)
Autoradiogram of a northern blot of total RNA extracted from cultures of a normal
control (C) and an IV-affected individual (IV). Total RNA was isolated from cultures at
one day preconfluence (–1), at confluence (C), and at 3, 7, 14, and 21 days post-confluence
(13, 17, 114, and 121, respectively). The RNA was subjected to northern analysis as
described in Materials and Methods, and the blot probed with a repeat of profilaggrin (exon
3) cDNA (proFG), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), keratin 1 (K1),
loricrin (Lori) cDNA (39 specific). It should be noted that the intensity of the hybridization
signal generated from the profilaggrin probe does not reflect the relative abundance of the
RNA between a normal control (C) and an IV-affected individual (IV), as the specific
activity of the probe used in each hybridization and exposure time were not identical. (C)
Intensities of hybridization signals obtained from profilaggrin and GAPDH probes were
quantitated by PhosphorImager analysis. Each bar represents the ratio of signals between
the probes (FG/GA). The plot represents data generated from IV-affected individuals,
which shared similar trends to those from normal controls.
1991; Zhu et al, 1991). The half-life values of the profilaggrin mRNA
remained similar when HS26, which has a half-life of more than 20 h
(Vincent et al, 1993), was used in the normalization instead of GAPDH.
The decrease in half-life clearly indicates that reduced profilaggrin
mRNA in IV is caused by accelerated degradation of the transcript, and
confirms our previous report of selectively impaired post-transcriptional
control of the gene (Nirunsuksiri et al, 1995). On the other hand,
stability of other epidermal keratinocyte mRNA, such as K1 and
loricrin, was similar in normal control and IV-affected keratinocytes.
Figure 2. Profilaggrin mRNA half-life is decreased in IV-affected keratinocytes.
Post-confluent (13 day) human keratinocyte cultures were fed with fresh medium 10 h
prior to addition of 65 µM DRB and were harvested 0, 2, 4, 8, 10, and 12 h thereafter.
Total RNA was isolated and subjected to northern blot analysis (10 µg per lane). The
filter was sequentially hybridized with probes specific for a repeat of profilaggrin (exon 3)
cDNA (proFG), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), keratin 1 (K1),
loricrin (Lori) cDNA (39 specific), and the cDNA for human S26 ribosomal protein
(HS26). Representative northern blots used to generate data are shown. The data were
collected from keratinocytes cultured from control or IV-affected individuals. The transcript
levels shown on the graph are the ratios of the profilaggrin to the GAPDH mRNA levels
at each time point and are expressed as a percentage of 0 h. Differences between affected
and control cells were maintained when expressed relative to HS26. The apparent half-
life of the profilaggrin mRNA, presented as the mean determination of duplicate
experiments, was 9 h or greater for normal (n) and 2.2 h for IV-affected (d) keratinocytes.
Note that the 12 h data point for IV#2 was not present due to an insufficient number of
cells; and the half-life value for normal cells was based on the N#2 only because the
mRNA levels of the other two cell lines did not reach 50% before 12 h after the addition
of DRB.
Thus, the results indicated that in IV-affected keratinocytes the profil-
aggrin mRNA is intrinsically unstable as compared with normal adult
or newborn foreskin keratinocytes.
Protein synthesis inhibitors increase the steady-state level of
profilaggrin mRNA To determine if translation inhibitors could
alter steady-state levels of profilaggrin mRNA, keratinocytes obtained
from an IV-affected individual or a newborn foreskin were treated
with cycloheximide, which inhibits translation elongation and causes
the formation of stabilized polysomes. GAPDH served as an internal
control because its mRNA level remains unaltered in cells treated with
cycloheximide (Linial et al, 1985; Vincent et al, 1993). Under these
conditions, a marked increase in the profilaggrin mRNA level was
observed in both IV-affected and control cells (Fig 3). Noticeably, the
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Table I. Computed percentage estimates (mean percentage)
of profilaggrin RNA from IV and control groups at various
timesa
Group Time (h) mean %
IV 2 47.15
4 32.49
8 24.2
10 17.94
12 20.87
Control 2 91.42
4 76.76
8 68.47
10 62.21
12 65.14
aData were fitted to a mathematical model using the PROCMIX program of SAS, as
described in Materials and Methods. Computed percentage estimates (mean %) of the data
(Fig 2) given by the fitted model are shown for each combination of group and time.
These values indicate that, on average, the group mean for the IV group is about 44.3%
lower than the group mean for the normal group. The SD from this model within subjects
was 9.3%, and between subjects was 14.5%. The resulting estimates (mean %) indicate that
the level of the IV group was essentially past the half-life (50%) by 2 h post-treatment,
whereas the control group did not reach half-life average by the twelfth hour.
Figure 3. Cycloheximide increases the steady-state level of profilaggrin mRNA.
After 10 h in fresh medium, post-confluent (13 day) keratinocytes from newborn foreskin
(C) and IV-affected individuals (IV) were incubated for 2 h in the absence (–) or presence
(1) of 30 µg cycloheximide (CHX) per ml and total RNA was analyzed as described
earlier. Probes are a repeat of profilaggrin exon 3 (proFG) and GAPDH. Location of the
28S ribosomal RNA is indicated on the left.
effect was greater in the IV-affected keratinocytes due to the inherently
lower baseline level of profilaggrin mRNA in the cells.
We further analyzed the effect of other translation blockers (anisomy-
cin, emetine, pactamycin, and puromycin that act through different
mechanisms) on profilaggrin steady-state mRNA level in IV-affected
keratinocytes in order to identify the mechanism of increased mRNA
level. Normal, unaffected control keratinocytes were not included in
these studies because the aim was not to compare IV with control but
to investigate the mechanism of the response. In the presence of the
aforementioned inhibitors, there was a 2–10-fold increase in profilaggrin
mRNA (Fig 4A). The relative level of induction by these inhibitors
at the experimental concentrations was different but may not reflect
their maximal potential. The mRNA level of K1, which is expressed
early during epidermal differentiation and is also regulated at the post-
transcriptional level (Dlugosz and Yuspa, 1993), barely increased in
Figure 4. Protein synthesis inhibitors increase the steady-state levels of profilaggrin,
but not K1 or loricrin mRNA. Total mRNA was prepared from IV-affected keratinocytes
under control conditions without translational inhibitors (CON) or with 10 µg anisomycin
per ml, 30 µg CHX per ml, 10 µg emetine per ml, 10 µg pactomycin per ml, or 10 µg
puromycin per ml for 4 h. Northern analysis of the RNA was carried out using 32P-
random primed cDNA probes of a repeat of profilaggrin exon 3 and GAPDH (A), keratin
1 (K1) (B), and loricrin (Lori) (C). Intensities of hybridization signals were quantified by
PhosphorImager analysis. One representative blot reprobed against ribosomal protein HS26
revealed similar changes (not shown). Each bar represents the ratio of signals between
profilaggrin and GAPDH probes (FG/GA), or keratin 1 and GAPDH (K1/GA), or loricrin
and GAPDH (Lori/GA), and is a mean determination of duplicate experiments.
Figure 5. Profilaggrin gene transcription is reduced by cycloheximide. Nuclei
were isolated from IV-affected keratinocytes incubated without protein synthesis inhibitor
(–CHX) or with 30 µg cycloheximide (1CHX) per ml for 2 h. Nascent transcripts were
allowed to elongate in vitro in the presence of 32P-GTP as described (Nirunsuksiri et al,
1995) and equal cpm per ml, based on trichloroacetic acid precipitation, of each probe
were hybridized to nitrocellulose filters carrying GAPDH, keratin 1 (K1), a repeat of
profilaggrin exon 3 (proFG), loricrin (Lori), and pGEM-5. Hybridization signals were
quantified by PhosphorImager and plotted as ratios of profilaggrin and GAPDH or K1
and GAPDH. u, without cycloheximide; j, with 30 µg cycloheximide per ml.
certain cases (CHX and puromycin in Fig 4B) and not at all in
others. On the other hand, loricrin mRNA accumulation was not
affected (Fig 4C).
Elevated steady-state level of profilaggrin mRNA via inhibition
of translation is due to mRNA stabilization To establish whether
the cycloheximide-mediated increase in profilaggrin mRNA level was
due to mRNA stabilization or transcriptional activation, nuclear run-on
assays were performed. Nuclei isolated from IV-affected keratinocytes in
the presence and absence of cycloheximide were incubated with
radiolabeled GTP and the extracted RNA probe was hybridized
to denatured DNA fragments of different genes immobilized onto
nitrocellulose filters. As shown in Fig 5, profilaggrin gene transcription
in cells treated with cycloheximide was much lower than in untreated
cells. The result indicated that transcriptional elongation of the profil-
aggrin gene in IV-affected keratinocytes was suppressed following
treatment with cycloheximide, whereas that of K1 was slightly increased.
Transcription of loricrin was not detectable under the conditions
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Figure 6. Profilaggrin mRNA is stabilized by translational and transcriptional
inhibition. IV-affected keratinocytes were treated with cycloheximide (30 µg per ml) for
2 h before DRB (65 µM) was added. Total RNA was isolated at the indicated times after
addition of DRB and was analyzed as in Fig 2. Each bar represents the ratio of signals
between profilaggrin and GAPDH probes (FG/GA), and is a mean determination of
duplicate experiments.
described in the Materials and Methods. This suggested that the increase
in profilaggrin mRNA level caused by cycloheximide was mediated
by stabilization of the transcript.
To test the hypothesis, the half-life of profilaggrin mRNA in IV-
affected keratinocytes was measured in the presence of cycloheximide
using DRB. The cells were pretreated with cycloheximide for 2 h
before addition of DRB and mRNA decay was followed over the
ensuing 8 h. As shown in Fig 6, the levels of profilaggrin mRNA did
not progressively decrease during DRB and cycloheximide exposure.
The result indicated that the relatively short lived profilaggrin mRNA
in IV-affected keratinocytes was indeed stabilized in the presence of
cycloheximide, at least throughout the period tested.
A possible involvement of a labile trans-acting factor Further
studies were carried out to determine if stabilization of profilaggrin
mRNA caused by inhibition of protein synthesis was due to the decay
of a protein factor(s) involved in mRNA degradation. Cycloheximide
was added to IV-affected keratinocytes at increasing times before
addition of DRB, and incubation was continued for an additional 4 h.
The results demonstrated that the longer the protein synthesis is
inhibited, the less is the extent of profilaggrin mRNA decay (Fig 7A).
Under these conditions, K1 mRNA levels were marginally affected,
and there was no effect on loricrin mRNA (quantification not shown).
This supports the possibility of a labile protein which gradually
disappears following inhibition of protein synthesis.
Treatment of IV-affected keratinocytes with DRB caused a reduction
in profilaggrin mRNA levels, whereas a slower fall in the mRNA
occurred with keratinocytes from unaffected individuals (Fig 2);
however, prolonged incubation of IV-affected keratinocytes in the
presence of both cycloheximide and DRB resulted in a much higher
profilaggrin mRNA level than that observed in cells treated with
cycloheximide alone (Fig 7B). These results support the likely presence
of a labile trans-acting factor which normally destabilizes profilaggrin
mRNA; inhibition of its transcription (with DRB) as well as translation
(with cycloheximide) leads to mRNA stabilization and hence increases
the profilaggrin mRNA level.
Current evidence also indicates that certain, if not all, translation
blockers elicit super-induction via signal transduction pathways when
used at subinhibitory concentrations (Edwards and Mahadevan, 1992;
Davidoff and Mendelow, 1993, 1994; Cano et al, 1994). Hence, we
tested to determine if this was the case for profilaggrin mRNA in IV-
affected keratinocytes. The results indicated that concentrations of
Figure 7. Time dependence of cycloheximide treatment and synergistic effect of
CHX and DRB on profilaggrin mRNA stability. (A) Cycloheximide (30 µg per ml)
was added to keratinocytes at different times (3, 1, and 0 h) before addition of DRB
(65 µM) and cells were cultured for a further 4 h, after which total RNA was extracted.
For the control, DRB was added to the cells at the same time as the others without prior
treatment with cycloheximide. Probes were a repeat of profilaggrin exon 3 (proFG),
glyceraldehyde-phosphate dehydrogenase (GAPDH), keratin 1 (K1), and loricrin (Lori).
The position of the 28S ribosomal RNA is indicated on the right. Each bar represents a
ratio of hybridization intensities between profilaggrin and GAPDH mRNA (FG/GA)
obtained from PhosphorImager analysis and averaged from duplicate experiments. (B)
Northern analysis of total RNA from IV-affected keratinocytes under different conditions;
1CHX, cells with 30 µg cycloheximide per ml for 4 h; CON, cells without cycloheximide
or DRB; 1DRB, cells with 65 µM DRB for 4 h; 1CHX1DRB, cells with 30 µg
cycloheximide per ml for 2 h before addition of 65 µM DRB and further incubation for
4 h. Each bar represents the ratio of signals between profilaggrin and GAPDH probes
(FG/GA), and is averaged from duplicate experiments.
cycloheximide, anisomycin, and puromycin as low as 50 ng per ml
elicit a slight induction of profilaggrin mRNA (data not shown). Such
effects may or may not play a role in the increased mRNA level seen
in our study that utilized relatively high concentrations of inhibitors;
however, it is possible that profilaggrin mRNA stability may be
controlled by more than one regulatory pathway.
Allelic heterogeneity of the profilaggrin gene in IV The profil-
aggrin gene has been reported to be polymorphic in size due to allelic
differences in the number of filaggrin repeats located in exon 3 (Gan
et al, 1990). Though the number of repeats in the general population
has been determined to be between 10 and 12, the number in IV-
affected individuals has not been reported. We tested the allelic
differences in IV by analysis of DNA from several unaffected, related,
or age- and sex-matched normal controls and IV-affected individuals.
Estimation of the size and the number of repeats was performed
utilizing the EcoRV restriction sites that flank the entire coding region.
As shown in Fig 8(A), the analysis showed three different bands of
µ12.2, 13.25, and 14.2 kb corresponding to 10, 11, and 12 filaggrin
domains, respectively. The number of filaggrin domains varies between
10 and 12 in both IV and control individuals. No obvious differences
in distribution of the alleles was seen between the small numbers of
individuals in the two groups.
Bi-allelic expression of the profilaggrin gene in IV To determine
whether expression of the profilaggrin gene is mono- or bi-allelic, we
further analyzed profilaggrin transcript in several of the individuals
from Fig 8(A). In general, techniques such as PCR-based allelic typing
or hybridization using allele specific oligonucleotides are used to
determine transcript output from each of the two alleles; however, in
the case of the profilaggrin gene, the presence of individuals heterozyg-
ous for the number of filaggrin repeats facilitates the analysis. Total
RNA from keratinocytes obtained from control and IV-affected indi-
viduals was examined by northern analysis. An extended electrophoresis
time (8–10 h) was used to allow separation of the two allelic transcripts.
Figure 8(B) shows that in all the affected individuals studied, both
alleles were expressed at approximately an equal level. The ratios of
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Figure 8. Allelic heterogeneity and expression of the profilaggrin gene do not
differ between keratinocytes from normal controls and IV-affected individuals.
(A) Southern analysis of genomic DNA from IV-affected individuals (IV) and controls (C).
Five micrograms of genomic DNA was digested with Eco RV and electrophoresed on a
0.8% agarose gel in 1 3 tris-acetate-ethylenediamine tetraacetic acid buffer overnight. The
RNA was blotted onto a Genescreen plus membrane and probed with a random primed
probe made from a filaggrin domain. S11/12, S10/11, and S10/10 are known samples of
genomic DNA from individuals with profilaggrin genes containing 11 and 12, 10 and 11,
and 10 and 10 repeats of filaggrin units, respectively. IV-1 and C-1 are homozygous for
11 repeats; IV-2 is heterozygous for 11 and 12 repeats; C-2 and C-3 are heterozygous for
10 and 12 repeats; and IV-3 is heterozygous for 10 and 11 repeats. (B) Analysis of allelic
expression of the profilaggrin gene in keratinocytes from normal controls (C) and IV-
affected individuals (IV). Total RNA from several individuals (IV-2, C-2, IV-3, and C-3)
studied in part (A) was subjected to northern analysis after extended (8–10 h) electrophoresis
using the exon 3 probe. EB represents RNA from a subject with another skin disease and
is regarded as a control in this study. IV-4 is a subject with IV whose DNA was not
available for study in part (A). It should be noted that double the amount of the RNA
samples from IV-affected keratinocytes was loaded in order to obtain signal intensities
similar to the normal controls. Degradation of the RNA was due to the extended time of
electrophoresis.
expression of the smaller to the larger of the two alleles were calculated
from the raw data obtained from PhosphorImager analysis and were
found to be between 1.2 and 1.3 in all except the normal control in
lane C-2, whose larger allelic transcript was expressed at a lower level
for unknown reasons. This particular control was clinically unaffected
but had less apparent immunoreactive profilaggrin (Nirunsuksiri et al,
1995) than other normal controls. The observations suggest that the
ratio of allelic mRNA levels did not change in IV and thus there
appears to be no evidence for differential stability of the two allelic
transcripts. The results also indicate that a loss of heterozygosity or
transcriptional imprinting of the profilaggrin gene is unlikely to be
involved with the disease.
DISCUSSION
Previously we reported that transcription of the profilaggrin gene in
IV-affected keratinocytes is similar to normal controls, but only about
50% of the mRNA and 10% of the level of protein are present
(Nirunsuksiri et al, 1995). We show here that the mechanism for these
observations is a marked reduction of the half-life of profilaggrin
mRNA in IV-affected keratinocytes.
Based on the decay of mRNA following inhibition of transcription
using an adenosine analog (DRB), we have calculated t1/2 values for
profilaggrin mRNA in normal and IV-affected keratinocytes. The
average of duplicates from three experiments gave a t1/2 value of 2.2 h
for IV-affected cells and of at least 9 h for control cells, demonstrating
that the stability of profilaggrin mRNA in IV is vitally altered.
Our data on profilaggrin mRNA half-life for controls represent
measurements in both keratinocytes from neonatal foreskin and adult
epidermis, as no differences were seen between the two; however, the
data do not distinguish profilaggrin mRNA stability in nuclear and
cytoplasmic fractions due to the technical problems of working with
such a large mRNA as profilaggrin. It is possible that the difference in
profilaggrin mRNA stability between normal and IV keratinocytes lies
primarily in either the nucleus or cytoplasm.
We have also shown that the level of profilaggrin mRNA in cultured
keratinocytes is elevated in response to inhibition of global protein
synthesis. The effect was more pronounced in IV-affected cells as they
had a lower baseline level of profilaggrin mRNA. The increase was
clearly due to stabilization of the transcript, and was not a result of
increased transcription. Hence, profilaggrin mRNA in IV-affected
keratinocytes resembles several other more rapidly degraded transcripts
(e.g., those of proto-oncogenes; Wisdom and Lee, 1991), which are
stabilized by protein synthesis inhibitors. This effect is rather common
for short-lived transcripts and in many cases suggests involvement of
labile trans-acting proteins. Additionally the steady-state level of
profilaggrin mRNA was also increased in the presence of protein
synthesis inhibitors at low concentration, suggesting a possible induction
due to signal transduction, as observed in other systems (Cano et al,
1994; Davidoff and Mendelow, 1994).
The effect of protein synthesis inhibitors provides not only insights
into possible mechanisms of the increased profilaggrin mRNA degrada-
tion in IV, but also its turnover in normal keratinocytes. Elevated levels
of profilaggrin mRNA following inhibition of protein synthesis can
be explained in two ways, each of which is not mutually exclusive of
the other. First, the mRNA turnover depends upon ongoing translation
of the mRNA itself, as observed in several genes (Laird-Offringa et al,
1990 and references therein). Second, translation generates newly
synthesized trans-acting factor(s) necessary for RNA degradation.
Stabilization of the profilaggrin mRNA observed in IV-affected ker-
atinocytes treated with several translation blockers (which inhibit
translation via different and distinct mechanisms) supports the latter
possibility. Furthermore, the results of the experiment in which
cycloheximide and DRB were used together (Fig 7B) support the
view that transcription and translation of a labile protein is essential
for controlling profilaggrin mRNA stability.
A model for profilaggrin degradation Based on these studies we
propose that the steady-state level of profilaggrin mRNA is regulated
by a dynamic action of at least two trans-acting factors; a labile
destabilizing factor (e.g., a specific ribonuclease) present in both IV-
affected and control keratinocytes, and a stabilizing factor (e.g., an
RNA binding protein). In IV-affected keratinocytes, the stabilizing
factor may not be present or is nonfunctional, leaving profilaggrin
mRNA vulnerable to degradation. When CHX is added, the profilag-
grin mRNA level is augmented because translation of the labile
destabilizing factor is inhibited. When both CHX and DRB are added,
transcription and translation are both arrested and therefore the
profilaggrin mRNA level is even higher than with CHX alone.
Profilaggrin mRNA may be targeted by a specific ribonuclease
present in keratinocytes at terminal differentiation or the mRNA may
be degraded by a generic ribonuclease. Activities of ribonucleases
involved in control of RNA degradation have been reported in certain
mammalian systems (Coutts and Brawerman, 1993; Dompenciel et al,
1995), including the interferon-induced 2–5 A-dependent RNase (Sen
and Lengyel, 1992) whose level is increased upon cell growth arrest
and cell differentiation (Silverman, 1994).
The model requires that a stabilizing factor for profilaggrin mRNA
exists in normal keratinocytes. Several compelling studies have demon-
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strated the importance of RNA-binding proteins in controlling gene
expression (e.g., see Wang et al, 1995). Interestingly, several proteins
display RNA-binding ability in addition to their known functions
(Green et al, 1995; Chu et al, 1995; Richard et al, 1995). Recently,
mutations in genes encoding potential RNA binding proteins have
been reported as genetic causes of defective spermatogenesis (Ma et al,
1993) and fragile X syndrome (Siomi et al, 1994). In IV, a specific
RNA binding protein(s) for profilaggrin mRNA may be absent or
nonfunctional, resulting in the destabilization of profilaggrin mRNA.
The possible aberration of a profilaggrin mRNA stabilizing factor
in IV implies that the mRNA is more rapidly turned over and/or is
poorly translated in IV-affected keratinocytes. This also suggests that
at a particular point during terminal differentiation, there may be a
threshold level for profilaggrin protein to reach in order to assemble
into keratohyalin granules. In IV, even though the protein may be
normal, the level of expression might not reach the threshold necessary
to provide a sufficient level of normal profilaggrin, and thus no
keratohyalin granules are formed. As a consequence the protein also
undergoes degradation, resulting in depletion of the protein pool and
more apparent deficiency.
Are mutations within the profilaggrin gene responsible for IV?
Although this report provides new insights that IV may result from
alteration of the proteins that regulate profilaggrin mRNA turnover,
the possibility of mutation(s) in the profilaggrin gene is still valid.
Various underlying mechanisms due to mutation have been described
among autosomal dominant diseases in which mRNA of the defective
genes are reduced. One common theme is a nonsense or missense
mutation causing premature termination during translation and mRNA
degradation referred to as nonsense-mediated mRNA decay. In most
cases, the mutations accounting for reduced expression have been
located 59 of the sequences; however, mutations in the 39 region with
the same effect have been reported (Timchenko et al, 1995). Though
a mechanism of mRNA decay has not been fully elucidated, factors
and events involved in the process have been progressively identified
(Urlaub et al, 1989; Hagan et al, 1995; Zhang et al, 1995; Kugler
et al, 1995).
Our sequence analyses revealed no mutations in the 59 upstream
and 39 untranslated sequences (Nirunsuksiri et al, 1995); however,
there may be mutation(s) in an intron or in any of the coding sequences.
Exon 3 contains 10–12 highly homologous repeats of filaggrin sequences
that are also rich in GC content. It is possible that there is a point
mutation somewhere along the repeats, or certain regions may be GC
hot spots similar to several genes in which mutations have been found
and related to phenotypic defects (Timchenko et al, 1995). We have
not attempted to identify mutations in exon 3 because of the presence
of homologous sequences where slight sequence variations among
repeats are likely to mask variability due to mutation. A similar
circumstance is described in the polycystic kidney disease 1 gene (The
European Polycystic Kidney Disease Consortium, 1994). Like most
dominantly inherited disorders, clinical variability of IV has been
observed and documented (Manabe et al, 1991; Fleckman and
Brumbaugh, in preparation), suggesting that more than one type of
mutation may be involved.
Though our studies reveal that expression of the profilaggrin gene
is bi-allelic and coequal in IV, the possibility of mutation(s) in one of
the alleles has not been excluded; however, the result suggests that if
mutation(s) in the profilaggrin gene is involved, the mutant allele
appears to have a trans effect on its normal counterpart because both
allelic transcripts are unstable and yield little or no profilaggrin protein.
We conclude that the decreased level of profilaggrin in IV is a result
of increased degradation of the mRNA from both alleles, possibly due
to the lack of an RNA stabilizing factor(s). Further study is essential
to determine the underlying molecular mechanism(s) accounting for
the decreased profilaggrin mRNA stability and the pathomechanism
of this scaling skin disorder.
We are grateful to Barbara Hager for her expertise in tissue culture and protein gels, and
Dr. Seung-Joo Kang for preparation of primary keratinocytes and for his assistance in
half-life experiments. We thank Drs. David Yanez, Nancy Temkin, and Ephraim Kam
for the statistic analysis. We also thank Drs. Beverly A. Dale and Richard Presland for
critical reading of this manuscript, Drs. Dennis Roop and P. Fort for probes, and the
Upjohn Co. for the generous gift of Pactamycin. Autoradiographic analysis in this study
was carried out by the PhosphorImager Facility of the Markey Molecular Medicine
Center at the University of Washington. This work was supported by National Institutes
of Health Grants PO1 AM 21557, the Endowed Dermatology Research Fund, and
the Hammock Trust. A portion of this work was conducted through the Clinical Research
Center facility of the University of Washington supported by the National Institutes of
Health (NIH) National Center for Research Resources (NCRR) Grant M01-
RR-00037.
REFERENCES
Anton-Lamprecht I, Hofbauer M: Ultrastructural distinction of autosomal dominant
ichthyosis vulgaris and X-linked ichthyosis. Humangenetik 15:261–264, 1972
Belasco JG, Brawerman G: Control of RNA Stability. Academic Press, San Diego, 1993.
Cano E, Hazzalin CA, Mahadevan LC: Anisomycin-activated protein kinases p45 and p55
but not mitogen-activated protein kinases ERK-1 and 22 are implicated in the
induction of c-fos and c-jun. Mol Cell Biol 14:7352–7362, 1994
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159, 1987
Chu E, Takechi T, Jones KL, et al: Thymidylate synthase binds to c-myc RNA in human
colon cancer cells and in vitro. Mol Cell Biol 15:179–185, 1995
Coutts M, Brawerman G: A 59 exoribonuclease from cytoplasmic extracts of mouse
sarcoma 180 ascites cells. Biochim et Biophys Acta 1173:57–62, 1993
Daujat M, Clair P, Astier C, et al: Induction, regulation and messenger half-life of
cytochromes P450 IA1, IA2 and 3A6 chromosome location in the rabbit and
evidence that post-transcriptional control of gene IA2 does not involve mRNA
stabilization. Eur J Biochem 200:501–510, 1991
Davidoff AN, Mendelow BV: Protein synthesis inhibition is not a requisite for puromycin-
and cycloheximide-induced c-myc mRNA superinduction. Anticancer Res 13:2257–
2260, 1993
Davidoff AN, Mendelow BV: Puromycin-elicited c-myc mRNA superinduction precedes
apoptosis in HL-60 leukaemic cells. Anticancer Res 14:1199–1202, 1994
Decker CJ, Parker R: Mechanisms of mRNA degradation in eukaryotes. TIBS 19:309–
34826, 1994
Dlugosz AA, Yuspa SH: Coordinate changes in gene expression which mark the spinous
to granular cell transition in epidermis are regulated by protein kinase C. J Cell Biol
120:217–225, 1993
Dompenciel RE, Garnepudi VR, Schoenberg DR: Purification and characterization of an
estrogen-regulated Xenopus liver polysomal nuclease involved in the selective
destabilization of albumin mRNA. J Biol Chem 270:6108–6118, 1995
Edwards DR, Mahadevan LC: Protein synthesis inhibitors differentially superinduce c-fos
and c-jun by three distinct mechanisms: lack of evidence for labile repressors. EMBO
J 11:2415–2424, 1992
Flach J, Bossie M, Vogel J, Corbett A, Jinks T, Willins DA, Silver PA: A yeast RNA-
binding protein shuttles between the nucleus and the cytoplasm. Mol Cell Biol
14:8399–8407, 1994
Fleckman P, Dale BA: Structural protein expression in the ichthyoses. In: Shrart B, Schaefer
H (eds). Pharmacology and the Skin, Vol. 5. Karger, Basel, 1993, pp. 1–15
Fleckman P, Holbrook K, Dale BA, Sybert VP: Keratinocytes cultured from subjects with
ichthyosis vulgaris are phenotypically abnormal. J Invest Dermatol 88:640–645, 1987
Gan S-Q, McBride OW, Idler WW, Markova N, Steinert PM: Organization, structure,
and polymorphisms of the human profilaggrin gene. Biochemistry 29:9432–9440, 1990
Genovese C, Milcarek C: Increased half-life of mu immunoglobulin mRNA during mouse
B cell development increases its abundancy. Mol Immuno 27:733–743, 1990
Green SR, Manche L, Mathews MB: Two functionally distinct RNA-binding motifs in
the regulatory domain of the protein kinase DAI. Mol Cell Biol 15:358–364, 1995
Hagan KW, Ruiz-Echevarria MJ, Quan Y, Peltz SW: Characterization of cis-acting
sequences and decay intermediates involved in nonsense-mediated mRNA turnover.
Mol Cell Biol 15:809–823, 1995
Harrold S, Genovese C, Kobrin B, Morrison SL, Milcarek C: Comparison of apparent
mRNA half-life using kinetic labeling techniques vs decay following administration
of transcriptional inhibitors. Anal Biochem 198:19–29, 1991
Hentze MW: Determinants and regulation of cytoplasmic mRNA stability in eukaryotic
cells. Biochim Biophys Acta 1090:281–292, 1991
Hua J, Hod Y: The role of protein synthesis in the decay of phosphoenolpyruvate
carboxykinase messenger RNA. Mol Endocrinol 6:1418–1424, 1992
Jimenez A, Carrasco L, Va´zquez D: Enzymic and nonenzymic translocation by yeast
polysomes. Site of action of a number of inhibitors. Biochemistry 16:4727–4730, 1977
Koeller DM, Horowitz JA, Casey JL, Klausner RD, Harford JB: Translation and the
stability of mRNAs encoding the transferrin receptor and c-fos. Proc Natl Acad Sci
USA 88:7778–7782, 1991
Kugler W, Enssle J, Hentze MW, Kulozik AE: Nuclear degradation of nonsense mutated
beta-globin mRNA. a post-transcriptional mechanism to protect heterozygotes from
severe clinical manifestations of beta-thalassemia? Nucl Acids Res 23:413–418, 1995
Laird-Offringa IA, de Wit CL, Elfferich P, Van Der EB, AJ: Poly(A) tail shortening is the
translation-dependent step in c-myc mRNA degradation. Mol Cell Biol 10:6132–
6140, 1990
Linial M, Gunderson N, Groudine M: Enhanced transcription of c-myc in bursal lymphoma
cells requires continuous protein synthesis. Science 230:1126–1132, 1985
Ma K, Inglis JD, Sharkey A, et al: A Y chromosome gene family with RNA-binding
VOL. 110, NO. 6 JUNE 1998 STABILITY OF PROFILAGGRIN MRNA IN ICHTHYOSIS VULGARIS 861
protein homology: candidates for the azoospermia factor AZF controlling human
spermatogenesis. Cell 75:1287–1295, 1993
Manabe M, Sanshez M, Sun TT, Dale BA: Interaction of filaggrin with keratin filaments
during advanced stages of normal human epidermal differentiation and in ichthyosis
vulgaris. Differentiation 48:43–50, 1991
Markova NG, Marekov LN, Chipev DC, Gan S-Q, Idler WW, Steinert PM: Profilaggrin
is a major epidermal calcium-binding protein. Mol Cell Biol 13:613–625, 1993
McKinley-Grant LJ, Idler WW, Bernstein IA, et al: Characterization of a cDNA clone
encoding human filaggrin and localization of the gene to chromosome region 1q21.
Proc Natl Acad Sci USA 86:4848–4852, 1989
McKusick VA: Mendelian Inheritance in Man, 10th edn. The Johns Hopkins University
Press, Baltimore, 1992, p. 397
Mevorah B, Krayenbuhl A, Bovey EH, Van Melle GD: Autosomal dominant ichthyosis
and X-linked ichthyosis. Comparison of their clinical and histological phenotypes.
Acta Derm Venereol Stockh 71:431–434, 1991
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA
from human nucleated cells. Nucl Acids Res 16:1215, 1988
Nirunsuksiri W, Presland R, Brumbaugh S, Dale BA, Fleckman P: Decreased profilaggrin
expression in ichthyosis vulgaris is a result of selectively impaired posttranscriptional
control. J Biol Chem 270:871–876, 1995
Peltz SW, Brewer G, Bernstein P, Hart PA, Jeffrey R: Regulation of mRNA turnover in
eukaryotic cells. Crit Rev Eucaryotic Gene Exp 1:99–126, 1991
Presland RB, Haydock PV, Fleckman P, Nirunsuksiri W, Dale BA: Characterization of
the human epidermal profilaggrin gene. Genomic organization and identification of
an S-100-like calcium binding domain at the amino terminus. J Biol Chem 267:23772–
23781, 1992
Presland RB, Bassuk JA, Kimball JR, Dale BA: Characterization of two distinct calcium-
binding sites in the amino-terminus of human profilaggrin. J Invest Dermatol 104:218–
223, 1995
Rawlings AV, Scott IR, Harding CR, Bowser PA: Stratum corneum moisturization at the
molecular level. J Invest Dermatol 103:731–741, 1994
Richard S, Yu D, Blumer KJ, Hausladen D, Olszowy MW, Connelly PA, Shaw AS:
Association of p62, a multifunctional SH2- and SH3- domain-binding protein, with
src family tyrosine kinases, Grb2, and phospholipase C gamma-1. Mol Cell Biol
15:186–197, 1995
Sachs AB: Messenger RNA degradation in eukaryotes. Cell 74:413–421, 1993
Sambrook J, Fritsch EF, Maniatis T (eds). Molecular Cloning-Laboratory Manuals, Vol. 2.
Eukaryotic Cells. Cold Spring Harbor Laboratory Press, New York, 1989, pp.
9.17–9.19
SAS: Technical Report P-229, SAS/STAT, Software Changes and Enhancement, Release
6.07, 1992, pp. 287–368
Scammell JG, Valentine DL: Induction of secretogranin II mRNA by protein synthesis
inhibitors in GH4C1 cells. Am J Physiol 267:E656–E661, 1994
Scott IR, Harding CR, Barrett JG: Histidine-rich protein of the keratohyalin granules.
Source of the free amino acids, urocanic acid and pyrrolidone carboxylic acid in the
stratum corneum. Biochim Biophys Acta 719:110–117, 1982
Sehgal PB, Darnell JE Jr, Tamm I: The inhibition by DRB (5,6-dichloro-1-beta-d-
ribofuranosylbenzimidazole) of hnRNA and mRNA production in. HeLa cells. Cell
9:473–480, 1976
Sen GC, Lengyel P: The interferon system. A bird’s eye view of its biochemistry. J Biol
Chem 267:5017–5020, 1992
Silverman RH: Fascination with 2–5A-dependent RNAse: a unique enzyme that functions
in interferon action. J Interferon Res 14:101–104, 1994
Siomi H, Choi M, Siomi MC, Nussbaum R, Dreyfuss G: Essential role for KH domains
in RNA binding: impaired RNA binding by a mutation in the KH domain of
FMR1 that causes fragile X syndrome. Cell 77:33–39, 1994
Sybert VP, Dale BA, Holbrook KA: Ichthyosis vulgaris: identification of a defect in
synthesis of filaggrin correlated with an absence of keratohyaline granules. J Invest
Dermatol 84:191–194, 1985
Taupin J-L, Qingsheng T, Kedersha N, Robertson M, Anderson P: The RNA-binding
protein TIAR is translocated from the nucleus to the cytoplasm during Fas-mediated
apoptotic cell death. Proc Natl Acad Sci USA 92:1629–1633, 1995
The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1
gene encodes a 14 Kb transcript and lies within a duplicated region on chromosome
16. Cell 77:881–894, 1994
Timchenko L, Monckton DG, Caskey CT: Myotonic dystrophy: an unstable CTG repeat
in a protein kinase gene. In: Seminars in Cell Biology, Vol. 6, Academic Press, San
Diego, 1995, pp. 13–19
Urlaub G, Mitchell PJ, Ciudad CJ, Chasin LA: Nonsense mutations in the dihydrofolate
reductase gene affect RNA processing. Mol Cell Biol 9:2868–2880, 1989
Va´zquez D: Inhibitors of protein biosynthesis. In: Kleinzeller A, Springer GF, Wittman
HG (eds). Molecular Biology, Biochemistry and Biophysics, Vol. 30. Springer-Verlag,
New York, 1979, pp. 513–527
Venrooij WJ van, Eenbergen J van, Janssen APM: Effect of Anisomycin on the cellular
level of native ribosomal subunits. Biochemistry 16:2343–2348, 1977
Vincent S, Marty L, Fort P: S26 ribosomal protein RNA. an invariant control for gene
regulation experiments in eucaryotic cells and tissues. Nucl Acids Res 21:1498, 1993
Wang X, Kiledjian M, Weiss IM, Liebhaber SA: Detection and characterization of a 39
untranslated region ribonucleoprotein complex associated with human alpha-globin
mRNA stability. Mol Cell Biol 15:1769–1777, 1995
Weighardt F, Biamonti G, Riva S: Nucleo-cytoplasmic distribution of human hnRNP
proteins: a search for the targeting domains in hnRNP A1. J Cell Sci 108:545–
555, 1995
Wells RS, Kerr CB: Clinical features of autosomal dominant and sex-linked ichthyosis in
an English population. Br Med J 1:947–950, 1966
Wisdom R, Lee W: The protein-coding region of c-myc mRNA contains a sequence
that specifies rapid mRNA turnover and induction by protein synthesis inhibitors.
Genes Dev 5:232–243, 1991
Zhang S, Ruiz-Echevarria MJ, Quan Y, Peltz SW: Identification and characterization of
a sequence motif involved in nonsense-mediated mRNA decay. Mol Cell Biol
15:2231–2244, 1995
Zhu Y-Y, Schwartz RJ, Crow MT: Phorbol esters selectively downregulate contractile
protein gene expression in terminally differentiated myotubes through transcriptional
repression and message destabilization. J Cell Biol 115:745–754, 1991
